Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.smaller Cos. Regulatory News (BSV)

Share Price Information for Br.smaller Cos. (BSV)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.00 (0.00%)
Bid:
70.00
Ask:
73.00
Spread: 3.00 (4.286%)
Market Cap: £297.44m
BSV Live PriceLast checked at - London Stock Exchange

Intraday Br.smaller Cos. Share Chart

1st Quarter Results

13 Sep 2023 07:00

RNS Number : 2903M
British Smaller Companies VCT PLC
13 September 2023
Β 

British Smaller Companies VCT plc

Interim Management Statement

For the quarter ended 30 June 2023

British Smaller Companies VCT plc (the "Company") presents its interim management statement for the quarter ended 30 June 2023. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

In the quarter to 30 June 2023, the Company's Net Asset Value per share return was unchanged at 83.7 pence. In comparison, the FTSE Small Cap Index fell by 0.4 per cent during the period. AIC data ranks the Company first across all generalist VCTs when considering a blended average performance ranking over 1, 3, 5, 7 and 10 years.

The Company's Total Return at 30 June 2023 was unchanged at 258.6 pence per ordinary share.

During the quarter, the Company invested Β£2.6 million into Workbuzz, an employee insights and engagement settlement platform. The Company also invested a further Β£0.8 million into Relative Insight.

The Company realised its investment in Ncam in April, generating initial proceeds of Β£1.4 million. There is the potential for additional receipts of up to Β£1.2 million depending on the achievement of certain milestones over the coming years, which would see the Company fully recover its investment; Β£0.3 million of deferred proceeds have been recognised at the period end.

Subsequent to the period end, the Company has made a further investment of Β£0.3 million into Elucidat.

Performance

The table below sets out movements in key metrics for the Company.Β 

Β 

Β 

31 March 2023

Increase in Value

Shares issued

Buyback of shares

Movement

In Period

30 June 2023

Net Assets (Β£m)

157.0

0.4

44.4

(0.4)

44.4

201.4

NAV per share (PPS)

83.7

0.2

(0.2)

-

-

83.7

Cumulative dividends paid (PPS)

174.9

-

-

-

-

174.9

Total Return (PPS)

258.6

0.2

(0.2)

-

-

258.6

Shares in issue

187,679,279

-

53,559,905

(451,965)

53,107,940

240,787,219

Cumulative dividends paid at 30 June 2023 were unchanged at 174.9 pence per ordinary share (31 March 2023: 174.9 pence per ordinary share).

The movements in NAV and NAV per ordinary share are set out in the table below:

Β 

Β 

Β£m

Pence per

ordinary share

NAV at 31 March 2023

157.0

83.7

Increase in portfolio value

0.6

0.3

Net operating costs

(0.2)

(0.1)

0.4

0.2

Issue/buy-back of shares*

44.0

(0.2)

Total Return in the period

44.4

-

NAV at 30 June 2023

Β 

201.4

Β 

83.7

Β 

* The allotment of shares from the 2022/23 fundraising reduced total return per ordinary share as the fundraising was priced at the last reported NAV at the time of the allotment of 82.8 pence per ordinary share, being the NAV as at 31 December 2022 of 87.3 pence per ordinary share, adjusted for the special interim dividend of 4.5 pence per ordinary share paid on 11 January 2023.

Β 

Post-period end, on 28 July 2023, a dividend of 2.0 pence per ordinary share for the year ending 31 March 2024 was paid, resulting in a corresponding reduction to the 30 June 2023 unaudited NAV, to 81.7 pence per ordinary share.

Dividends and shares in issue

On 4 April 2023, the Company allotted 53,559,905 shares following the close of its 2022/23 fundraising.

Under its standing buyback authority, on 26 June 2023 the Company purchased 451,965 shares at 80.02 pence at a cost of Β£0.36 million. These shares are held in treasury.Β 

Subsequent to the quarter end, on 28 July 2023 the Company issued 1,270,231 shares under the Company's Dividend Re-investment Scheme (DRIS) following the payment of the interim dividend, taking the number of shares in issue at that date to 242,057,450, with a further 22,459,730 shares held in treasury.

Net assets

Net assets at 30 June 2023 comprised the following:

Β£000

% of net assets

Unquoted investments at fair value

125,850

62.5

Listed investment funds

3,745

1.9

Cash and cash equivalents

69,854

34.7

Other net assets

1,993

0.9

Net assets

201,442

100.0

Investments

The investment portfolio at 30 June 2023 comprised:

Valuation

Β£000

Cumulative valuation as a % of net assets

Matillion

24,886

12.4%

Unbiased

10,511

17.6%

Displayplan

8,829

22.0%

Outpost

8,680

26.3%

Wooshii

6,981

29.7%

Elucidat

6,226

32.8%

Force24

4,758

35.2%

Vypr

4,159

37.2%

ACC Aviation

4,095

39.3%

Quality Clouds

4,032

41.3%

Β 

83,157

41.3%

Other investments

42,693

21.2%

Total investments

125,850

62.5%

Portfolio performance

Over the quarter to 30 June 2023, the aggregate unquoted portfolio valuation has increased by Β£0.8 million.

Fundraising

On 4 April 2023 the Company allotted shares from its fully subscribed 2022-23 share offer. Β£44.4 million was raised by the Company, resulting in the allotment of 53,559,905 ordinary shares.

On 2 August 2023, the Company announced its intention to launch a joint offer for subscription for the 2023-24 tax year later this year, alongside British Smaller Companies VCT2 plc. A prospectus with full details of the proposed Offer is expected to be published in mid-to-late September.

Outlook

Portfolio companies continue to show resilience in navigating a challenging macro environment, charting a path that balances continued growth with a move towards profitability. While rising interest rates will slow economic growth, a more capital constrained environment reduces competition and alternative funding sources, providing opportunities for further deployment of capital for the Company, in both new and existing portfolio companies. In this vein, the Company continues to see a healthy pipeline of opportunities in which to invest in fast growing British businesses.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

13 September 2023

For further information please contact:

David Hall YFM Private Equity Limited Tel: 0113 244 1000

Alex Collins Panmure Gordon (UK) Limited Tel: 0207 886 2767

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
QRFEALNDFAXDEEA
Date   Source Headline
22nd Jun 20264:32 pmRNSTransaction in Own Shares
11th Jun 202612:15 pmRNSAnnual Financial Report
20th Apr 202610:00 amRNSAdmission to Trading
1st Apr 20269:00 amRNSIssue of Equity
27th Mar 20264:10 pmRNSTransaction in Own Shares
23rd Mar 202610:45 amRNSPublication of a Supplementary Prospectus
19th Mar 20267:00 amRNS3rd Quarter Results
30th Jan 20267:00 amRNSAdmission of Further Securities to Trading
7th Jan 20269:30 amRNSIssue of Equity
23rd Dec 20258:54 amRNSAmendments to AIFM Agreements
23rd Dec 20258:54 amRNSAmendments to AIFM Agreements
22nd Dec 20259:13 amRNSTransaction in Own Shares
22nd Dec 20259:13 amRNSTransaction in Own Shares
19th Dec 202510:02 amRNSPayment of Dividend and Issue of Equity
19th Dec 202510:02 amRNSPayment of Dividend and Issue of Equity
18th Dec 202512:14 pmRNSClose of Offers to new Applications
18th Dec 202512:14 pmRNSClose of Offers to new Applications
28th Nov 202510:00 amRNSHalf-year Financial Report
20th Nov 20259:00 amRNSOffer Update
11th Nov 20257:00 amRNSDividend Declaration
27th Oct 202511:00 amRNSNominal Capital Reduction
10th Oct 20253:41 pmRNSOffer Update
2nd Oct 20259:00 amRNSOffer Update
25th Sep 20259:04 amRNSPublication of a Prospectus
23rd Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSInterim Management Statement
9th Sep 202512:56 pmRNSResult of AGM
22nd Aug 202510:45 amRNSNew combined offer for subscription
25th Jul 202510:16 amRNSPayment of dividend and issue of Equity
24th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20251:30 pmRNSAnnual Financial Report
1st Apr 20258:02 amRNSDirector/PDMR Shareholding
1st Apr 20258:00 amRNSIssue of Equity
26th Mar 20255:13 pmRNSTransaction in Own Shares
24th Mar 202512:45 pmRNSPublication of Supplementary Prospectus
24th Mar 202512:45 pmRNSPublication of Supplementary Prospectus
18th Mar 20251:00 pmRNS3rd Quarter Results
30th Jan 20259:05 amRNSDirector/PDMR Shareholding
30th Jan 20259:00 amRNSIssue of Equity
27th Jan 20259:23 amRNSPayment of dividend and issue of shares
8th Jan 20252:14 pmRNSClose of Offer to new Applications
8th Jan 20252:13 pmRNSClose of Offer to new Applications
20th Dec 20249:26 amRNSPayment of dividend and issue of equity
17th Dec 20247:00 amRNSDividend Declaration
16th Dec 20245:09 pmRNSTransaction in Own Shares
29th Nov 20249:00 amRNSHalf-year Report
20th Nov 20241:00 pmRNSOffer Update
20th Nov 20241:00 pmRNSOffer Update
14th Nov 20247:48 amRNSDividend Declaration
1st Nov 20247:00 amRNSOffer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.